Lv1
100 积分 2025-08-18 加入
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
20天前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
1个月前
已完结
Long-term survival outcomes with immune checkpoint inhibition in PD-L1 low or intermediate expressing gastroesophageal adenocarcinoma
1个月前
已关闭
Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study
1个月前
已完结
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
2个月前
已完结
Risk-adaptive Therapy Guided by Dynamic ctDNA in Nasopharyngeal Carcinoma
2个月前
已完结
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Artificial intelligence-based pathological model for pan-cancer lymph node metastasis detection: a multicentre diagnostic study with retrospective and prospective validation
2个月前
已完结
Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial
2个月前
已完结
皖公网安备34019202002308
